Zeo ScientifiX (ZEOX) CEO awarded two 625K stock option grants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Zeo ScientifiX, Inc. reported that CEO, CFO and 10% owner Ian T. Bothwell received two grants of stock options on June 10, 2026. Each grant covers 625,000 options to buy common stock at an exercise price of $1.67 per share.
The first grant vested in full on the grant date and is exercisable on a cashless basis for ten years under the company’s 2021 Equity Incentive Plan. The second grant also covers 625,000 options, vests upon achievement of specified performance milestones, is exercisable cashless for up to ten years, and is described as antidilutive for future transactions issuing 10% or more of fully diluted common shares. These are compensation-related awards, not open‑market share purchases.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
BOTHWELL IAN T
Role
CEO & CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 625,000 | $0.00 | -- |
| Grant/Award | Stock Options | 625,000 | $0.00 | -- |
Holdings After Transaction:
Stock Options — 625,000 shares (Direct, null)
Footnotes (1)
- Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan (the "2021 Plan"). The options vested in full as of the grant date, are exercisable on a "cashless basis" for a period of ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan. Represents the grant of stock options to purchase shares of the Issuer's common stock under the 2021 Plan. The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis" during the period commencing on the date they vest and ending ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan. The options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company's common stock outstanding on a fully diluted basis.
Key Figures
Option grant size (time-vested): 625,000 options
Option grant size (performance-based): 625,000 options
Exercise price: $1.67 per share
+3 more
6 metrics
Option grant size (time-vested)
625,000 options
Fully vested grant on June 10, 2026
Option grant size (performance-based)
625,000 options
Performance-milestone grant on June 10, 2026
Exercise price
$1.67 per share
Conversion/exercise price for both option grants
Expiration date
June 10, 2036
Ten-year term from award date for each grant
Transaction code
A (grant/award acquisition)
Compensation-related acquisitions, not open-market buys
Underlying common stock
625,000 shares per grant
Each option grant relates to common stock under 2021 Plan
Key Terms
2021 Equity Incentive Plan, cashless basis, performance milestones, antidilutive
4 terms
2021 Equity Incentive Plan financial
"Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan"
cashless basis financial
"The options vested in full as of the grant date, are exercisable on a "cashless basis" for a period of ten (10) years"
An agreement executed on a cashless basis lets a holder convert or exercise a security (like options, warrants, or conversion rights) without paying money upfront; instead the holder receives a smaller number of shares equal in value to what the cash would have purchased. Think of trading a coupon for fewer slices of a cake rather than handing over cash for the full slice. For investors, it affects how much ownership and dilution occur and avoids immediate cash outlays.
performance milestones financial
"The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis""
antidilutive financial
"The options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company's common stock"
FAQ
What did Zeo ScientifiX (ZEOX) disclose in this Form 4 filing?
Zeo ScientifiX disclosed that CEO, CFO and 10% owner Ian T. Bothwell received two stock option grants. Each grant covers 625,000 options to buy common shares at an exercise price of $1.67 under the 2021 Equity Incentive Plan.
How many stock options did ZEOX CEO Ian Bothwell receive?
Ian Bothwell received two separate stock option grants of 625,000 options each. Both grants relate to Zeo ScientifiX common stock and were awarded on June 10, 2026 under the company’s 2021 Equity Incentive Plan as compensation.
What are the terms of Ian Bothwell’s fully vested ZEOX option grant?
One grant of 625,000 options vested in full on the grant date. These options are exercisable on a cashless basis for ten years from June 10, 2026 and are subject to all other terms of Zeo ScientifiX’s 2021 Equity Incentive Plan.
How do the performance-based ZEOX stock options for Ian Bothwell work?
The second 625,000-option grant vests only when specified performance milestones are achieved. Once vested, the options are exercisable on a cashless basis for ten years and are characterized as antidilutive if future deals issue 10% or more of fully diluted common shares.
Are Ian Bothwell’s ZEOX option grants open-market stock purchases?
No, these are compensation-related option awards, not open-market purchases of common stock. The Form 4 describes them as grants under the 2021 Equity Incentive Plan, with no cash paid per option on the grant date.
What does cashless exercise mean for the ZEOX stock options granted?
Cashless exercise allows Ian Bothwell to receive net shares without paying the exercise price in cash. Instead, a portion of the underlying shares is typically withheld to cover the exercise cost and related obligations under the plan.